Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131).

Authors

Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah M Drusbosky, Alice P Chen, Xiaofeng Zheng, Keyur Patel, Stanley R Hamilton, Mark Routbort, James V Tricoli, P Mickey Williams, A John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F Little, Carlos L Arteaga, Peter J O'Dwyer, Keith T Flaherty, Lyndsay N Harris, Funda Meric-Bernstam

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. May 19, 2025. Epub May 19, 2025.

Abstract

Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a non-invasive approach to identify actionable genomic alterations in advanced/metastatic cancers. Herein, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue-based sequencing.
We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma.
We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n=243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% (n=197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n=32) and had non-contemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allelic frequency, and based on tumor biopsy site.
The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patients' enrollment in trials evaluating biomarker-driven anticancer therapies.

PMID:
40388547
Bibliographic data and abstract were imported from PubMed on 20 May 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.